araag2/HINT huggingface dataset:
Clinical trial NCT00102804 (phase 3, status: completed)
Conditions: non-small cell lung cancer
ICD codes: C78.00, C78.01, C78.02, D14.30, D14.31, D14.32, C34.2
Drugs: pemetrexed, placebo
SMILES: [H][N]([H])([H])[Pt](Cl)(Cl)[N]([H])([H])[H], CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Histologic or cytologic diagnosis of NSCLC Stage IIIB (with pleural effusion and/or
             positive supraclavicular lymph nodes) or Stage IV prior to induction therapy.

          -  Participants must have had 1 of the following induction therapies for treatment for
             Stage IIIB (with pleural effusion and/or positive supraclavicular lymph nodes) or IV
             NSCLC: Gemcitabine plus carboplatin, paclitaxel plus carboplatin, or docetaxel plus
             carboplatin, gemcitabine plus cisplatin, paclitaxel plus cisplatin or docetaxel plus
             cisplatin.

          -  Participants must have received only 1 chemotherapeutic doublet lasting precisely 4
             cycles.

          -  Induction regimens must be based on 21-day cycles.

          -  Documented evidence of a tumor response of complete response (CR), partial response
             (PR), or stable disease (SD). Tumor assessment must occur between Cycle 4 (Day 1) of
             induction therapy and the date of randomization. This response does not have to be
             confirmed in order for the participant to be randomized. Positron emission tomography
             (PET) scans and ultrasounds may not be used for lesion measurements for response
             determination.

        Exclusion Criteria:

          -  With the exception of those chemotherapies listed as inclusion criterion, participants
             will not be included if they have received prior systemic anticancer therapy
             (including adjuvant early-stage treatment for NSCLC) or any systemic treatment for any
             other cancer.

          -  Have received treatment within the last 30 days with a drug that has not received
             regulatory approval for any indication at the time of study entry.

          -  Inability to comply with protocol or study procedures.

          -  A serious concomitant systemic disorder that would compromise the participant's
             ability to complete the study.

          -  A serious cardiac condition, such as myocardial infarction within 6 months, angina, or
             heart disease, as defined by the New York Heart Association Class III or IV.
Clinical trial NCT01048866 (phase 3, status: completed)
Conditions: pharyngitis
ICD codes: A54.5, J02.0, J31.2, B08.5, J02.9, A50.03, J02.8
Drugs: placebo, flurbiprofen, acetaminophen 650mg
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, CC(C(O)=O)C1=CC(F)=C(C=C1)C1=CC=CC=C1, CC1=CC(O)=CC(C)=C1Cl
Eligibility criteria:

        Inclusion Criteria:

          1. The patient has a complaint of sore throat.

          2. If the patient is a female of childbearing potential, she has been using effective
             contraception since the last date of menses and is not breast-feeding or lactating.

          3. If the patient is a female of childbearing potential, the patient must have a negative
             urine pregnancy.

          4. The patient has provided written informed consent prior to any study-related
             procedures.

        Exclusion Criteria:

          1. The patient has a history of an upper gastrointestinal ulcer within the past 60 days,
             is currently experiencing clinically significant upper gastrointestinal complaints, or
             is currently taking medication regularly (≥ three times in the previous week).

          2. The patient has a history of any hepatic disease or renal dysfunction.

          3. The patient has a history of chronic analgesic use (≥ three times per week over the
             prior four weeks). (Patients on low-dose aspirin therapy may be allowed in the study
             per investigator's clinical decision.)
Clinical trial NCT01567995 (phase 3, status: completed)
Conditions: eczema
ICD codes: B00.0, L20.82, L20.84, L20.83, H01.131, H01.132, H01.133
Drugs: clobetasone butyrate 0.05% cream, vehicle (base cream)
SMILES: [H][C@]1(C)C[C@@]2([H])[C@]3([H])CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)C(=O)C[C@]2(C)[C@@]1(O)C(=O)CCl, CC1=CC(O)=CC(C)=C1Cl
Eligibility criteria:

        Inclusion Criteria:

          -  Subjects with a diagnosis of eczema, fulfil the 3 follow items: 1) Erythema,
             papilla/water blister, Lichenification, skin damage with infiltration, 2) unknown
             reason, recurrent attacks; 3) itching in diseased skin

          -  Subjects must have body surface area (BSA) disease involvement of less than or equal
             to 10% as assessed by palm method

          -  Subject must present with moderate and above eczema as defined by a score greater than
             or equal to 3 using the investigators global assessment (IGA) of eczema severity.

        Exclusion Criteria:

          -  The subject presents with any systemic disorder or active skin disease (e.g.
             psoriasis) that would in any way confound interpretation of the study results or
             subjects who present with scars, moles, tattoos, body piercings, sunburn in the test
             area which could interfere with the assessment of lesions at screening.

          -  The subject has eczema restricted to the face, the feet or the hands only.

          -  The subject is indicated any anti-infectives drug for a current complication of overt
             bacterial, fungal and viral infection

          -  History of recent (<1 month) active or presence of current superficial skin infections
             of viral aetiology such as herpes simplex, or varicella.

          -  The subject has been exposed to below therapy within the set timeframe: Topical agents
             administered in the diseased skin, including emollient - 1 week; Systemic
             administration of anti-histamine agents - 2 week; Systemic administration of
             corticosteroid -4 week; Systemic administration of immunosuppressive drugs - 4 week;
             UV therapy -4 week

          -  Foreseeable intensive ultraviolet (UV) exposure during the study (solar or
             artificial). Subjects must not be exposed to intense direct sunlight for long periods,
             and must not use skin tanning devices (e.g. sunbed) for the duration of the study.

          -  History of clinically significant cardiovascular, pulmonary, gastrointestinal, liver,
             neurological, renal or haematological abnormalities.

          -  History of allergy to components of test medications to be used in the study.

          -  History of anaphylaxis (a sudden, potentially life-threatening systemic allergic
             reaction) to food, medications, insect venom, or latex.
Clinical trial NCT01584648 (phase 3, status: completed)
Conditions: melanoma
ICD codes: C43.0, C43.31, D03.9, C43.51, C43.9, D03.0, C43.4
Drugs: dabrafenib, trametinib, trametinib placebo
SMILES: CC(C)(C)C1=NC(=C(S1)C1=NC(N)=NC=C1)C1=C(F)C(NS(=O)(=O)C2=C(F)C=CC=C2F)=CC=C1, CN1C(=O)C(C)=C2N(C(=O)N(C3CC3)C(=O)C2=C1NC1=CC=C(I)C=C1F)C1=CC(NC(C)=O)=CC=C1, CN1C(=O)C(C)=C2N(C(=O)N(C3CC3)C(=O)C2=C1NC1=CC=C(I)C=C1F)C1=CC(NC(C)=O)=CC=C1
Eligibility criteria:

        Inclusion Criteria:

          -  Histologically confirmed cutaneous melanoma that is either Stage IIIC (unresectable)
             or Stage IV (metastatic), and determined to be BRAF V600E/K mutation-positive using
             the bioMerieux (bMx) investigational use only (IUO) THxID BRAF Assay (IDE: G120011).
             The assay will be conducted by a central reference laboratory. Subjects with ocular or
             mucosal melanoma are not eligible.

          -  The subject must have a radiologically measurable tumor

          -  The subject is able to carry out daily life activities without significant difficulty
             (ECOG performance status score of 0 or 1).

          -  Able to swallow and retain oral medication

          -  Sexually active subjects must use acceptable methods of contraception during the
             course of the study

          -  Adequate organ system function and blood counts

        Exclusion Criteria:

          -  Prior treatment with a BRAF or a MEK inhibitor

          -  Prior systemic anti-cancer treatment for Stage IIIC (unresectable) or Stage IV
             (metastatic) melanoma. Prior systemic treatment in the adjuvant setting is allowed.
             (Note: Ipilimumab treatment must end at least 8 weeks prior to randomization.)

          -  The subject has received major surgery or certain tyes of cancer therapy with 21 days
             of starting treatment

          -  Current use of prohibited medication listed in the protocol

          -  Left ventricular ejection fraction less than the lower limit of normal

          -  Uncontrolled blood pressurl

          -  History or current evidence of retinal vein occlusion or central serous retinopathy

          -  Brain metastases unless previously treated with surgery or stereotactic radiosurgery
             and the disease has been stable for at least 12 weeks

          -  The subject is pregnant or nursing
Clinical trial NCT01062360 (phase 3, status: completed)
Conditions: common cold, pharyngitis
ICD codes: J00, T48.5X6S, T48.5X3S, T48.5X4S, T48.5X5S, T48.5X6A, T48.5X6D, A54.5, J02.0, J31.2, B08.5, J02.9, A50.03, J02.8
Drugs: acetylsalicylic acid (aspirin complex, baye4465) + pseudoephedrine, acetylsalicylic acid (aspirin, baye4465), pseudoephedrine, placebo
SMILES: COC1=C(OC)C=C2C3CC(=O)C(CC(C)C)CN3CCC2=C1, CC(=O)OC1=CC=CC=C1C(O)=O, COC1=C(OC)C=C2C3CC(=O)C(CC(C)C)CN3CCC2=C1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:- Male and female subjects between 18 and 65 years of age.- Onset of
        cold symptoms within 96 hours (4 days) before study participation.- Current complaint of at
        least moderate sore throat at baseline- Current complaint of at least moderate NC at
        baseline- History of other symptoms associated with URTI during the last 4 days before
        study participation.- Other findings of URTI, confirmed on the physical examination.-
        Agreement to comply with the study requirements.- Written informed consent prior to
        enrollment in the study Exclusion Criteria:- Pregnant or lactating females.- Uncontrolled
        chronic diseases.- History of hypersensitivity (allergic reaction) to ASA, any other
        nonsteroidal anti-inflammatory drugs (NSAIDs), or PSE.- Any disease which significantly
        compromises breathing or interferes with the subjects assessment of sore throat.- History
        of or active peptic ulcer.- Severe impaired hepatic function.- Severe impaired renal
        function.- Simultaneous intake of monoamine oxidase inhibitors.- Use of menthol containing
        tissues within 2 hours before first intake of study drug.- Intake of any menthol containing
        product within 4 hours before first intake of study drug.- Use of any local or systemic
        short acting cough and cold preparations within 6 hours before first intake of study drug.-
        Use of any local or systemic long acting cough and cold preparations within 12 hours before
        first intake of study drug.- Intake of any analgesic within 12 hours before first intake of
        study drug.- Intake or requirement of any prescription medication for the treatment of the
        current acute respiratory tract infection.- Current or previous intake of anticoagulants,
        corticoids, NSAIDs, methotrexate, or lithium.- Participation in another clinical trial
        within the last 30 days.
Clinical trial NCT01310777 (phase 3, status: completed)
Conditions: open-angle glaucoma, ocular hypertension
ICD codes: H40.10X0, H40.10X1, H40.10X2, H40.10X3, H40.10X4, H40.1130, H40.1131, H40.053, H40.051, H40.052, H40.059
Drugs: brinzolamide 1%/brimonidine tartrate 0.2% ophthalmic suspension, brinzolamide 1% ophthalmic suspension, brimonidine tartrate 0.2% ophthalmic solution
SMILES: BrC1=C(NC2=NCCN2)C=CC2=NC=CN=C12, CCN[C@H]1CN(CCCOC)S(=O)(=O)C2=C1C=C(S2)S(N)(=O)=O, BrC1=C(NC2=NCCN2)C=CC2=NC=CN=C12
Eligibility criteria:

        Inclusion Criteria:

          -  Diagnosed with open angle glaucoma or ocular hypertension, and, in the opinion of the
             Investigator, are insufficiently controlled on monotherapy or are currently on
             multiple IOP-lowering medications.

          -  Meet qualifying IOP entry criteria.

          -  Able to understand and sign an informed consent form.

          -  Other protocol-specified inclusion criteria may apply.

        Exclusion Criteria:

          -  Women of childbearing potential if pregnant, test positive for pregnancy at Screening
             Visit, breastfeeding, or not in agreement to use adequate birth control methods to
             prevent pregnancy throughout the study.

          -  Severe central visual field loss.

          -  Best corrected visual acuity (BCVA) score worse than 55 ETDRS letters (20/80 Snellen
             equivalent).

          -  Chronic, recurrent or severe inflammatory eye disease.

          -  Ocular trauma within the preceding 6 months.

          -  Ocular infection or ocular inflammation within the preceding 3 months.

          -  Clinically significant or progressive retinal disease.

          -  Other ocular pathology.

          -  Intraocular surgery within the 6 months prior to entry.

          -  Ocular laser surgery within the 3 months prior to entry.

          -  Any abnormality preventing reliable applanation tonometry.

          -  Any other conditions, including severe illness, which would make the subject, in the
             opinion of the Investigator, unsuitable for the study.

          -  Recent use of high-dose (>1 gram daily) salicylate therapy.

          -  Recent, current, or anticipated treatment with any medication that augments adrenergic
             responses, or precludes use of an alpha-adrenergic agonist.

          -  Concurrent use of glucocorticoid medications administered by any route.

          -  Other protocol-specified exclusion crtieria may apply.
Clinical trial NCT00205777 (phase 3, status: completed)
Conditions: osteoporosis
ICD codes: M81.6, Z82.62, Z13.820, M81.8, Z87.310, M81.0, M80.80XS
Drugs: bazedoxifene acetate
SMILES: CC1=C(N(CC2=CC=C(OCCN3CCCCCC3)C=C2)C2=C1C=C(O)C=C2)C1=CC=C(O)C=C1
Eligibility criteria:

        Inclusion Criteria:

          -  Must be at least 2 years postmenopausal

          -  Osteoporotic subjects without vertebral fracture who meet BMD criteria, or
             Osteoporotic subjects with vertebral fracture

        Exclusion Criteria:

          -  Diseases that may affect bone metabolism

          -  Vasomotor symptoms requiring treatment

          -  Known history or suspected cancer of the breast

          -  Active or past history of venous thromboembolic events
Clinical trial NCT01695902 (phase 3, status: completed)
Conditions: heavy menstrual bleeding
ICD codes: G43.831, G43.839, G43.821, G43.829, N94.9, N94.89
Drugs: levosert-20, mirena
SMILES: [H][C@@]12CC[C@@](O)(C#C)[C@@]1(CC)CC[C@]1([H])[C@@]3([H])CCC(=O)C=C3CC[C@@]21[H]
Eligibility criteria:

        Inclusion Criteria:

          -  Non-pregnant, non-planning pregnancy, non-lactating non-menopausal females at least 18
             years of age.

          -  Patients with a clinical diagnosis of functional Menorrhagia during the last 6 months.

          -  Patients who are eligible and able to participate in the trial and who consent to do
             so in writing after the purpose and nature of the investigation have been explained to
             them.

        Exclusion Criteria:

          -  History of endometrial ablation or dilatation and/or curettage within the 3 months
             prior to screening

          -  Copper - coiled-intrauterine device or LNG releasing IUS use within 2 months prior to
             screening

          -  Abnormal liver function or jaundice

          -  Renal insufficiency

          -  Other hormonal treatment (sexual steroids),

          -  Organic causes of abnormal uterine bleeding (presence of endometrial polyps, submucous
             myomas of any size, or myometrial myomas > than 3 cm, adenomyosis, atypical
             hyperplasia, carcinoma)

          -  Abnormal uterine morphology

          -  Presence of ovarian cyst > 3 cm

          -  Lower genital tract infection

          -  Current or recurrent PID (present or recurrent pelvis infection (including history of
             postpartum endometritis, infected miscarriage) during the past 3 months

          -  Uncontrolled hypertension

          -  Congenital or acquired valvular disease (including corrections with prosthetic valves)

          -  Known or suspected pregnancy

          -  Known or suspected hormone-dependent tumor

          -  BMI > 30

          -  Abnormal Pap smear test or other evidence of cervical/endometrial mancy

          -  Unexplained amenorrhea

          -  Known hypersensitivity to device material and/or Levonorgestrel
Clinical trial NCT00455936 (phase 3, status: completed)
Conditions: lung cancer
ICD codes: C78.00, C78.01, C78.02, D14.30, D14.31, D14.32, C34.2
Drugs: gefitinib
SMILES: COC1=C(OCCCN2CCOCC2)C=C2C(NC3=CC(Cl)=C(F)C=C3)=NC=NC2=C1
Eligibility criteria:

        Inclusion Criteria:

          1. Histologically or cytologically confirmed diagnosis of adenocarcinoma of lung with or
             without BAC features; however, adenocarcinoma combined with other histology, such as
             small cell carcinoma or squamous carcinoma, is not allowed.

          2. Stage IIIB with malignant pleural effusion/pleural seeding or stage IV patients

          3. Age 18-75

          4. Never-smoking defined as not more than 100 cigarettes during the lifetime

          5. ECOG performance status of 0-2

          6. No prior invasive malignancies 5 years prior to study entry except adequately treated
             cutaneous basal cell carcinoma or uterine cervix in situ cancer

          7. Serum creatinine ≤ 1.5 mg/dL, serum bilirubin ≤ 1.2 mg/dL (1 x UNL) and SGOT/SGPT ≤
             100 IU/L (2.5 x UNL)

          8. Serum Hgb ≥ 10 gm/dl, platelet count ≥ 100,000/ul, total WBC count >= 4,000/uL,
             absolute neutrophil count ≥ 1,500/ul

          9. Patients must sign an informed consent indicating that they are aware of the
             investigational nature of the study in keeping with the policy of the hospital. The
             only approved consent form is attached to this protocol

         10. The presence of CNS metastases is not considered as an exclusion criterion, provided
             that there is good control of the symptoms with corticosteroids

        Exclusion Criteria:

          1. Pregnancy or breast-feeding (women of child-bearing potential). Women of childbearing
             potential must practice acceptable methods of birth control to prevent pregnancy.

          2. Major surgery other than biopsy within the past two week.

          3. Known severe hypersensitivity to Gefitinib or any of the excipients of this product

          4. Any evidence of clinically active interstitial lung disease (patients with chronic,
             stable, radiographic changes who are asymptomatic need not be excluded)

          5. As judged by the investigator, any evidence of severe or uncontrolled systemic disease
             (e.g., unstable or uncompensated respiratory, cardiac, hepatic, or renal disease)

          6. Evidence of any other significant clinical disorder or laboratory finding that makes
             it undesirable for the subject to participate in the study

          7. Concomitant use of phenytoin, carbamazepine, rifampicin, barbiturates, or St John's
             Wort

          8. Treatment with a non-approved or investigational drug within 30 days before Day 1 of
             study treatment.
Clinical trial NCT00408876 (phase 3, status: completed)
Conditions: back pain without radiation
ICD codes: K62.7, G62.82, N46.024, N46.124, T66.XXXS, Z57.1, N52.35
Drugs: duloxetine, placebo
SMILES: CN(C)CCC[C@]1(OCC2=C1C=CC(=C2)C#N)C1=CC=C(F)C=C1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria: - Male/Female outpatients 18 years of age with chronic low back pain.
        Exclusion Criteria: - You have a serious or unstable disease of the heart or blood vessels,
        liver, kidney, lungs, or blood-related illness, problems with decreased blood flow to arms
        and legs (peripheral vascular disease), or other medical conditions, or psychiatric
        conditions that, in the opinion of the investigator, would affect your participation or be
        likely to lead to hospitalization during the course of the study. - Have acute liver injury
        (such as hepatitis) or severe cirrhosis. - Have had previous exposure to duloxetine. - Have
        a body mass index (BMI) over 40. - Have major depressive disorder. - Require daily
        narcotics.
Clinical trial NCT01081834 (phase 3, status: completed)
Conditions: diabetes mellitus, type 2
ICD codes: E11.65, E11.9, E11.21, E11.36, E11.41, E11.42, E11.44
Drugs: canagliflozin, placebo, sitagliptin
SMILES: [H][C@]1(O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O)C1=CC=C(C)C(CC2=CC=C(S2)C2=CC=C(F)C=C2)=C1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, N[C@@H](CC(=O)N1CCN2C(C1)=NN=C2C(F)(F)F)CC1=CC(F)=C(F)C=C1F
Eligibility criteria:

        Inclusion Criteria:

          -  All patients must have a diagnosis of T2DM

          -  Patients in the main study must have a Hemoglobin A1c (HbA1c) between >=7% and <=10%
             and a fasting plasma glucose (FPG) <270 mg/dL (15 mmol/L)

          -  Patients in the High Glycemic Cohort Substudy must have an HbA1c between >10% and
             <=12% and a FPG <=350 mg/dL (19.44 mmol/L)

        Exclusion Criteria:

          -  History of diabetic ketoacidosis, type 1 diabetes mellitus (T1DM), pancreas or beta
             cell transplantation, diabetes secondary to pancreatitis or pancreatectomy, or a
             severe hypoglycemic episode within 6 months before screening
Clinical trial NCT00510484 (phase 3, status: completed)
Conditions: cystic fibrosis
ICD codes: E84.9, Z14.1, E84.0, E84.11, E84.8, E84.19, P09.4
Drugs: pancrelipase delayed release, placebo comparator
SMILES: [Na+].[Cl-]
Eligibility criteria:

        Inclusion Criteria:

          -  Confirmed CF diagnosis by two positive chloride sweat tests or gene analysis

          -  Confirmed PEI by historical CFA < 70% without supplementation or current or historical
             fecal elastase < 50µg/g stool (within the last 12 months)

          -  Subjects of 12 years or older

          -  Currently receiving treatment with a commercially available pancreatic enzyme product
             on a stable dose for more than 3 months

          -  Clinically stable condition without evidence of acute respiratory disease or any other
             acute condition

          -  Females of child-bearing potential must agree to continue using a medically acceptable
             method of birth control

        Exclusion Criteria:

          -  Ileus or acute abdomen

          -  History of fibrosing colonopathy

          -  History of distal ileal obstruction syndrome within 6 months of enrollment

          -  Use of an immunosuppressive drug

          -  Any type of malignancy involving the digestive tract in the last 5 years

          -  Known infection with HIV